Aberdeen Group Reduces Stake in Vertex Pharmaceuticals

robot
Abstract generation in progress

Aberdeen Group plc, a major institutional investor, decreased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 16.8% during the fourth quarter of 2025. The firm’s 13F filing shows it now holds 262,057 shares worth $118.81 million. This reduction suggests a potential shift in investor sentiment regarding the biotech company, which focuses on treatments for serious diseases like cystic fibrosis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin